Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

Richard S. Finn, John Crown, Istvan Lang, Katalin Boer, Igor Bondarenko, Sergey O. Kulyk, Johannes Ettl, Ravindranath Patel, Tamas Pinter, Marcus Schmidt, Yaroslav V. Shparyk, Anu Thummala, Nataliya L. Voytko, Camilla Fowst, Xin Huang, Sindy Kim, Dennis J. Slamon

David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
Irish Cooperative Oncology Research Group, Dublin, Ireland
National Institute of Oncology, Budapest, Hungary
Szent Margit Korhaz, Onkologia, Budapest, Hungary
Dnepropetrovsk State Medical Center, Dnipropetrovsk, Ukraine
Municipal Treatment-and-Prophylactic Institution, Donetsk, Ukraine
Technical University of Munich, Munich, Germany
Comprehensive Blood and Cancer Center, Bakersfield, CA
Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary
Johannes Gutenberg Universität, Mainz, Germany
Lviv State Oncological Regional Medical and Diagnostic Center, Lviv, Ukraine
Comprehensive Cancer Centers of Nevada, Las Vegas, NV
Kyiv City Clinical Oncology Center, Kyiv, Ukraine
Pfizer Italia Srl, Milan, Italy
Pfizer Inc., La Jolla, CA
Pfizer Inc., San Diego, CA